SCHEMBL17449002

SCHEMBL17449002

CCCCC(=O)OC1(C)CC(O)=CC(C)(C)O1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRKCA P17252 3/20 0.34
▸ NFKB1 P19838 2/20 0.33
▸ STAT1 P42224 2/20 0.33
▸ NFKB2 Q00653 2/20 0.33
▸ RELA Q04206 2/20 0.33
▸ MIF P14174 1/20 0.33
▸ NLRP3 Q96P20 1/20 0.32
▸ MEN1 O00255 2/20 0.31
▸ KMT2A Q03164 2/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ RECQL P46063 1/20 0.31
▸ ALOX5 P09917 1/20 0.31
▸ PTGS1 P23219 1/20 0.31
▸ PTGS2 P35354 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ HSD17B3 P37058 1/20 0.30
▸ CYP3A4 P08684 1/20 0.30
▸ HPGD P15428 1/20 0.30
▸ PRKCD Q05655 1/20 0.30
▸ MLNR O43193 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16118316 0.80 LPL (0.32) PRKCANFKB1STAT1NFKB2RELA
SCHEMBL17449162 0.80 NFKB1 (0.32) PRKCANFKB1STAT1NFKB2RELA
SCHEMBL17449005 0.78 MIF (0.33) PRKCAMIFNLRP3MEN1KMT2A
SCHEMBL16118390 0.76 — —
SCHEMBL16118389 0.74 PRKCA (0.35) PRKCANFKB1STAT1NFKB2RELA
SCHEMBL17449017 0.72 PKM (0.38) MEN1KMT2AKDM4EALDH1A1MAPT
SCHEMBL17449161 0.67 NFKB1 (0.31) PRKCANFKB1STAT1NFKB2RELA
SCHEMBL16118347 0.64 PRKCA (0.30) PRKCAPRKCD
SCHEMBL14985533 0.62 CYP19A1 (0.44) PRKCAALDH1A1LMNAMAPT
SCHEMBL13564624 0.61 CYP19A1 (0.46) PRKCAMEN1KMT2AALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170158678-A1 SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2017-06-08 — — US disclosed
US-20160016942-A1 SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2016-01-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160016942-A1 SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS C-FMS KINASE INHIBITORS FLT3, ABL1, FES PRKCA 152/4885NFKB1 1070/4885STAT1 721/4885
US-20170158678-A1 SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS C-FMS KINASE INHIBITORS FLT3, ABL1, FES PRKCA 152/4885NFKB1 1070/4885STAT1 721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback